Breaking Advances
Cancer Res November 15 2010 70 (22) 8971-8972; DOI:10.1158/0008-5472.CAN-70-22-BA
IDH1 mutations create a higher dependence of glioma cells on α-ketoglutarate, relative to normal cells, that could be therapeutically exploited by targeting glutamine metabolism.
Findings implicate a chaperone network in controlling mitochondrial permeability transition and apoptosis in cancer cells.
The study presents TOP2A as a superior prognostic marker for prostate cancer and shows that its predictive ability is dependent on cancer subtype.
This study defines suitable doses, accompanying blood levels, and potential efficacy biomarkers which might help to optimize future cancer chemoprevention intervention studies of the red wine constituent resveratrol.
Mass spectrometry imaging techniques can identify different tissue microenvironments in breast tumors, possibly improving their clinicopathological assessment in the future.
Methods that improve PET imaging in cancer offer opportunities for improved detection and management.
Findings define methods to achieve strong antigen-specific immunity and cancer cures using antigen-encoding RNA in preclinical animal models.
Correcting tumoral immune escape exerts therapeutic effects against established tumors by improving the delivery of antitumor T cells into the tumor microenvironment.
Findings offer preclinical proof-of-concept for a novel adoptive T cell transfer approach for cancer treatment that can potentiate antitumor effects and complement approaches using retroviral and lentiviral engineered T-cell therapies.
Clinical findings confirm expectations of a stringent correlation between the therapeutic efficacy of a dendritic cell vaccine and the extent of immunogenic death induced in the tumor cells used to load the dendritic cells before vaccination.
In this study, efficient T-cell selection was combined with SNP genotyping to discover a significant number of new minor histocompatibility antigens that can be targeted by cellular immunotherapy of cancer.
Mechanistic findings define a transcriptional cascade that plays a critical role in quenching HER2/neu oncogenic signals known to promote breast cancer.
Findings offer a rationale to target a master transcriptional regulator of antioxidant genes and Phase II detoxifying enzymes as an anticancer strategy, also suggesting it as a novel theranostic biomarker.
Findings elucidate how a key growth factor in prostate cancer acts at several levels to shut down a central pathway of epithelial cell function in the prostate, with important therapeutic implications for prostate cancer management.
An important mitotic kinase that is targeted by small molecule inhibitors currently in clinical testing is found to have an important role in supporting metastasis.
Esophageal cancer can be detected by metabolic profiling of adjacent histologically normal mucosa.
Findings elucidate microRNA-mediated control of a common mitogen in a variety of human cancers, the regulation of which had been previously obscure, with implications for microRNA-based therapeutic targeting.
Findings report a novel preclinical model and a rationale to evaluate rapamycin therapy for salivary gland acinic cell carcinoma, a low grade neoplasm but one that tends to recur.
Fumarate hydratase deficiency compels cells to prematurely adopt a metabolic phenotype that predisposes them to cell proliferation and growth and ultimately to cancer.
Findings identify a candidate genetic marker of prognosis in follicular lymphoma, which may provide an explanation as to why its treatment with rituximab provides less benefit in some patients.
Findings offer significant new insights into how the estrogen receptor is deregulated in breast cancer.
Findings define a functionally important alternative splicing mechanism in lung adenocarcinoma that offers a novel approach to therapeutic development.
Findings define a homeobox protein that positively modifies a variety of oncogenic signals in ovarian cancer, with potential prognostic applications.
Study implicates a DNA helicase regulated by Rb-E2F as an important driver of metastatic progression of prostate cancer.
Accumulating evidence argues that serum levels of vitamin D exert a profound influence on cancer risk, as illustrated in this study of bladder cancer.
Study offers an excellent illustration of how an environmental modifier can radically alter the impact of a genetic risk marker on a patient's susceptibilty to disease.
A common immunohistopathological marker used for staging of clinical cancers may offer unexpected opportunities as a therapeutic target.
Findings identify a reversible novel mechanism of resistance to the alkylating agent temozolomide in pediatric glioblastoma model systems and patient samples.
Findings suggest a novel theranostic molecule in advanced prostate cancer to predict responses to taxane therapy and to improve treatment of taxane-resistant disease.
An antitumor compound previously found to block signaling by Jak2 kinase is found to target deubiquitinases that are commonly overexpressed in cancer cells.
A novel approach to remodel the tumor vasculature has strongly positive pharmacokinetic consequences on cancer drug delivery in a preclinical model, resulting in better therapy and survival outcomes.
A major ROS-producing enzyme in the heart is implicated in adverse cardiac remodeling caused by doxorubicin chemotherapy, implying a new therapeutic strategy to reduce doxorubicin cardiotoxicity.
Results define an autocrine mechanism controlled by the nuclear receptor ERRα, associated with poor outcomes in several cancers, that influences cancer cell migratory capacity.
Mechanistic findings suggest a potential surrogate marker that could be useful to predict the efficacy of Sorafenib in liver cancer.
A 3D model for ovarian micrometastases is introduced as a high-throughput platform to report treatment response, exemplified in this study to show how photodynamic therapy synergistically enhances carboplatin efficacy.
Studies in mice suggest that voluntary exercise can alleviate progressive memory loss after cranial irradiation, strongly prompting studies in clinical settings.
Results illustrate the potential of combining engineered oncolytic virotherapy and ionizing radiation as a strategy to improve the management of human cancer.
Genetic ablation of Brick1, a component of the Wave/Scar actin regulatory complex, appears to exert a protective effect against malignant development in renal cancer and other cancers where loss occurs.
Findings illuminate understanding of how EGF activates the mTORC2 growth regulatory complex to drive breast cancer metastasis, with implications for clinical studies of mTOR inhibitors.
More sensitive and specific tumor detection technologies are needed to rapidly assess surgical resection margins and to monitor residual tumor cells that may persist in blood after disease treatment.
Expectations that mice lacking both the p16INK4 and p21WAF1 tumor suppressor genes would be highly susceptible to carcinogenesis is experimentally confirmed and mechanistically dissected in this study.
Phosphoproteomic profiling reveals that basal breast cancer cells are characterized by an extensive Src family kinase signalling network, highlighting candidate theranostic targets for this aggresive subtype of breast cancers.
Findings suggest that the prognostic significance of a chromatin coregulator for hormone receptors in breast cancer is based on its role in integrating multiple oncogenic programs, with particular importance to aggressive triple-negative tumors.
Results identify a novel role for FAK and Src in regulating tumor cell movement in vivo using fluorescence based microscopy.
Findings point to the nuclear receptor HNF4α as a potential therapeutic target to modify epithelial cell resistance to ROS production during intestinal tumorigenesis.
Findings support the definition of a new tumor suppressor located at chromosome 13q14 and suggest its possible utility in predicting cancer chemosensitivity.
Studies of a stem cell marker in breast cancer cells suggest its potential as a therapeutic target.
Findings suggest that characteristic elevations in lipogenesis in cancer cells contribute to tumor growth not by improving membrane biosynthesis, as commonly believed, but by modifying fundamental developmental signaling and cell polarity.
Findings offer evidence that cancer stem cells may arise through cellular reprogramming-like mechanisms.
As the most abundant tumor suppressor microRNA in human embryonic stem cells, miR-302 offers an appealing focus for the development of a universal cancer therapeutic.
An enzyme that functions inside cells in glycolysis and gluconeogenesis has a second extracellular function that in cancer provides a critical support for invasive cell motility, EMT, and metastasis.
Findings offer preclinical proof-of-concept for a highly tractable and attractive new approach to target cancer stem cells in cancer therapy.
Findings offer preclinical proof-of-concept that simultaneous inhibition of more than one cellular antioxidant system could be highly effective in killing tumor cells via redox modifiers.
Results identify a transcription factor in the FOXM1 family that can hijack adult human stem cells to jump start cancer initiation.